SCHEMBL897272

SCHEMBL897272

C[N]C(=O)Nc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.58
NAPRT Q6XQN6 1/20 0.58
EPHX1 P07099 2/20 0.56
TP53 P04637 1/20 0.56
TSHR P16473 1/20 0.56
EPHX2 P34913 1/20 0.56
CDK9 P50750 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
GAA P10253 4/20 0.52
ALDH1A1 P00352 4/20 0.50
LMNA P02545 3/20 0.50
MAPT P10636 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
ATM Q13315 1/20 0.50
KMT2A Q03164 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
CYP3A4 P08684 1/20 0.50
TAS2R38 P59533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11650361 0.81 EPHX2 (0.61) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL10457010 0.81 EPHX2 (0.61) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL3175598 0.79 SMN1; SMN2 (0.58) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL8392332 0.78 NAPRT (0.54) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL4589529 0.78 MEN1 (0.56) SMN1; SMN2GAAALDH1A1LMNAMAPT
SCHEMBL5313666 0.77 SMN1; SMN2 (0.56) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL5681693 0.77 EPHX2 (0.56) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL9360689 0.77 EPHX2 (0.56) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL8393640 0.77 SMN1; SMN2 (0.56) HSD17B10NAPRTEPHX1TP53TSHR
SCHEMBL8396654 0.77 TP53 (0.56) HSD17B10NAPRTEPHX1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US claimed
EP-1440976-B1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production BOEHRINGER INGELHEIM PHARMA (DE) 2008-07-23 EP claimed
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2004-10-28 US claimed
EP-1440976-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-07-28 EP claimed
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2003-04-10 US claimed
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2001-11-01 US claimed
EP-0927192-A1 MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION Dr. Karl Thomae GmbH (DE) 1999-07-07 EP claimed
WO-1998011128-A1 MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION DR. KARL THOMAE GMBH (DE) 1998-03-19 WO claimed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 US disclosed
US-11345914-B2 Composition for delivering nucleic acid and nucleic acid-containing composition TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES (JP) 2022-05-31 US disclosed
CN-107249589-B Physiologically active substance-binding block copolymer 日本化药株式会社 2021-06-08 CN disclosed
US-20210115440-A1 NUCLEIC ACID DELIVERY COMPOSITION, AND NUCLEIC ACID-CONTAINING COMPOSITION TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES (JP) 2021-04-22 US disclosed
EP-3263107-B1 BLOCK COPOLYMER CONJUGATE OF PHYSIOLOGICALLY ACTIVE SUBSTANCE NIPPON KAYAKU KK (JP) 2020-11-11 EP disclosed
US-4075162-A BICHROMOPHORIC BENZOXAZOLE-STYRENE ULTRAVIOLET STABILIZERS AND THEIR USE IN ORGANIC COMPOSITIONS EASTMAN KODAK COMPANY (US) 1978-02-21 US disclosed
US-4073745-A Multichromophoric benzotriazole ultraviolet stabilizers and their use in organic compositions EASTMAN KODAK COMPANY (US) 1978-02-14 US disclosed
US-4070337-A Bichromophoric benzotriazole-styrene ultraviolet stabilizers and their use in organic compositions EASTMAN KODAK COMPANY (US) 1978-01-24 US disclosed
US-4070339-A Bichromophoric benzotriazole-styrene ester ultraviolet stabilizers and their use in organic compositions EASTMAN KODAK COMPANY (US) 1978-01-24 US disclosed
US-4062800-A Bichromophoric benzoxazole-styrene ester and amide ultraviolet stabilizers and their use in organic compositions EASTMAN KODAK COMPANY (US) 1977-12-13 US disclosed
US-3981884-A POLYMERS EASTMAN KODAK COMPANY (US) 1976-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 HSD17B10 2091/4885NAPRT 1804/4885EPHX1 2261/4885
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS HSD17B10 4618/4885NAPRT 4093/4885EPHX1 2612/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 HSD17B10 2091/4885NAPRT 1804/4885EPHX1 2261/4885
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 HSD17B10 4236/4885NAPRT 4191/4885EPHX1 2441/4885
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production SLC1A5, NEFM, SRMS HSD17B10 3992/4885NAPRT 4232/4885EPHX1 2183/4885
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 HSD17B10 4236/4885NAPRT 4191/4885EPHX1 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.